BioCryst Q3 ORLADEYO revenue $66M; on track to double 2022 sales; BCX9250 discontinued

BIOCRYST PHARMACEUTICALS INC

2022-Q3 EPS reported -$0.95 revenue$191,282,000

Q3 total revenue $75.8M (+85% YoY); net loss $42.5M ($0.23/share) vs $58.8M ($0.33) in Q3 2021.
ORLADEYO Q3 net revenue $66.0M; full-year 2022 guidance raised to $255M, more than double 2021.
BCX9930 partial clinical hold lifted; screening resumed; data from ~15 patients expected mid-2023.
New oral Factor D inhibitor BCX10013 entered clinic; preliminary data expected Q1 2023.
Discontinued BCX9250 (FOP) program to redirect ~$100M to complement pipeline.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

BIOCRYST PHARMACEUTICALS INC reported third quarter ended September 30, 2022 results: revenue $75.8 million, net income $42.5 million, EPS $0.23 per share.

Period: third quarter ended September 30, 2022
Revenue: $75.8 million
Net income: $42.5 million
EPS: $0.23 per share
Result: reported results

Exact text from the filing

For the three months ended September 30, 2022, total revenues were $75.8 million, compared to $41.0 million in the third quarter of 2021 (+85 percent year-over-year (y-o-y)). The increase was primarily due to $66.0 million in ORLADEYO net revenue in the third quarter of 2022. Research and development expenses for the third quarter of 2022 increased to $52.7 million from $50.0 million in the third quarter of 2021 (+6 percent y-o-y), primarily due to additional investment in the HAE program and expenses for BCX9250 prior to its discontinuation, partially offset by reduced costs related to the BCX9930 studies. Selling, general and administrative expenses for the third quarter of 2022 increased to $36.9 million, compared to $35.0 million in the third quarter of 2021 (+6 percent y-o-y). The increase was primarily due to increased investment to support the commercial launch of ORLADEYO. Interest expense was $24.8 million in the third quarter of 2022, compared to $14.1 million in the third qu

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

BIOCRYST PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001171843-22-006936

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.